Literature DB >> 10098426

A comparison of daily CT localization to a daily ultrasound-based system in prostate cancer.

J Lattanzi1, S McNeeley, W Pinover, E Horwitz, I Das, T E Schultheiss, G E Hanks.   

Abstract

PURPOSE: Daily CT localization has been demonstrated to be a precise method of correcting radiation field placement by reducing setup and organ motion variations to facilitate dose escalation in prostate carcinoma. The purpose of this study was to evaluate the feasibility and accuracy of daily ultrasound-guided localization utilizing daily CT as a standard. The relatively simple computer-assisted ultrasound-based system is designed to be an efficient means of achieving daily accuracy. METHODS AND MATERIALS: After five weeks of conformal external beam radiation therapy, 23 patients underwent a second CT simulation. Prostate-only fields based on this scan were created with no PTV margin. On each of the final conedown treatment days, a repeat CT simulation and isocenter comparison was performed. Ten of the above patients also underwent prostate localization with a newly developed ultrasound-based system (BAT) that is designed to facilitate patient positioning at the treatment machine. The portable system, which electronically imports the CT simulation target contours and isocenter, is situated adjacent to the treatment couch. Transverse and sagittal suprapubic ultrasound images are captured, and the system overlays the corresponding CT contours relative to the machine isocenter. The CT contours are maneuvered in three dimensions by a touch screen menu to match the ultrasound images. The system then displays the 3-D couch shifts required to produce field alignment.
RESULTS: The BAT ultrasound system produced good quality images with minimal operator training required. The localization process was completed in less than 5 min. The absolute magnitude difference between CT and ultrasound was small (A/P range 0 to 5.9 mm, mean 3 mm +/- 1.8; Lat. range 0 to 7.9 mm, mean 2.4 mm +/- 1.8; S/I range 0 to 9 mm, mean 4.6 mm +/- 2.8). Analysis confirmed a significant correlation of isocenter shifts (A/P r = 0.66, p < 0.0001; Lat. r = 0.58, p < 0.003; S/I r = 0.78, p < 0.0001) in all dimensions, and linear regression confirmed the equivalence of the two modalities.
CONCLUSIONS: Daily CT localization is a precise method to improve daily target localization in prostate carcinoma. However, it requires significant human and technical resources that limit its widespread applicability. Conversely, localization with the BAT ultrasound system is simple and expeditious by virtue of its ability to image the prostate at the treatment machine in the treatment position. Our initial evaluation revealed ultrasound targeting to be functionally equivalent to CT. This ultrasound technology is promising and warrants further investigation in more patients and at other anatomical sites.

Entities:  

Mesh:

Year:  1999        PMID: 10098426     DOI: 10.1016/s0360-3016(98)00496-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  37 in total

Review 1.  [Optimizing the use of radiotherapy with IMRT and image guided location of advanced prostate cancer].

Authors:  F Lohr; M Fuss; U Tiefenbacher; M Siegsmund; S Mai; J M Kunnappallil; B Dobler; P Alken; F Wenz
Journal:  Urologe A       Date:  2004-01       Impact factor: 0.639

Review 2.  Radiation therapy dose escalation for prostate cancer: a rationale for IMRT.

Authors:  Alan Pollack; Alex Hanlon; Eric M Horwitz; Steven Feigenberg; Robert G Uzzo; Robert A Price
Journal:  World J Urol       Date:  2003-09-05       Impact factor: 4.226

3.  [Image-guided radiation therapy].

Authors:  J Boda-Heggemann; M Guckenberger; U Ganswindt; C Belka; H Wertz; M Blessing; F Wenz; M Fuss; F Lohr
Journal:  Radiologe       Date:  2012-03       Impact factor: 0.635

4.  The observed variance between predicted and measured radiation dose in breast and prostate patients utilizing an in vivo dosimeter.

Authors:  Charles W Scarantino; Bradley R Prestidge; Mitchel S Anscher; Carolyn R Ferree; William T Kearns; Robert D Black; Natasha G Bolick; Gloria P Beyer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-01       Impact factor: 7.038

Review 5.  Current status and future prospects of multi-dimensional image-guided particle therapy.

Authors:  Shinichiro Mori; Silvan Zenklusen; Antje-Christin Knopf
Journal:  Radiol Phys Technol       Date:  2013-02-19

6.  Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled.

Authors:  Kris T Huang; Radka Stoyanova; Gail Walker; Kiri Sandler; Matthew T Studenski; Nesrin Dogan; Tahseen Al-Saleem; Mark K Buyyounouski; Eric M Horwitz; Alan Pollack
Journal:  Radiother Oncol       Date:  2015-05-08       Impact factor: 6.280

7.  Image-guided intensity-modulated radiotherapy for pancreatic carcinoma.

Authors:  Martin Fuss; Adrian Wong; Clifton D Fuller; Bill J Salter; Cristina Fuss; Charles R Thomas
Journal:  Gastrointest Cancer Res       Date:  2007-01

8.  Dosimetric comparison of image guidance by megavoltage computed tomography versus bone alignment for prostate cancer radiotherapy.

Authors:  Jörn Kalz; Florian Sterzing; Kai Schubert; Gabriele Sroka-Perez; Jürgen Debus; Klaus Herfarth
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

9.  cExternal beam radiation results in minimal changes in post void residual urine volumes during the treatment of clinically localized prostate cancer.

Authors:  Peter F Orio; Gregory S Merrick; Zachariah A Allen; Wayne M Butler; Kent E Wallner; Brian S Kurko; Robert W Galbreath
Journal:  Radiat Oncol       Date:  2009-07-22       Impact factor: 3.481

10.  Positional reproducibility and effects of a rectal balloon in prostate cancer radiotherapy.

Authors:  Jae Ho Cho; Chang-Geol Lee; Dae Ryong Kang; Jooho Kim; Sangkyu Lee; Chang-Ok Suh; Jinsil Seong; Yang Gun Suh; Ikjae Lee; Gwi Eon Kim
Journal:  J Korean Med Sci       Date:  2009-09-24       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.